R21/Matrix-M - single vial formulation for malaria

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 13 Dec 2021: Trial registered, NCT05155579
  2. 14 May 2022: Trial started, NCT05155579

The trials

NCT05155579: Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21/Matrix-M and Co-Administration With EPI Vaccines

State
Completed
Phase
Phase 1
People
594 taking part
Started
14 May 2022
Primary completion
27 May 2025
Arms
Group 1b, 2b and 3b, Group 4a, Group 4c, Group 5a, Group 6a, Group 6b
Results
None posted
  1. 13 Dec 2021: Trial registered
  2. 14 May 2022: Trial started
  3. 27 May 2025: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.